Press

Nebula Biocides receives millions in seed funding

November 10, 2021

Great success for Nebula Biocides GmbH: Three investors decide to invest in the Greifswald-based start-up company. This brings the business a major step closer to its goal of obtaining approval for the highly effective disinfectant Sporosan® and finally placing it on the market.

Greifswald, 10.11.2021 – With a total investment of 1.6 million euros, the start-up Nebula Biocides, founded in 2019, can now really take off: The approval of the novel disinfection process Sporosan® is supported through seed financing by the High-Tech Gründerfonds (HTGF), the Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern mbH (MBMV) and a strategic investor operating in the field of cleaning and disinfection equipment.

We are very pleased to have a strong business partner on board along with two experienced and highly networked financial investors

Dr. Jörn Winter, founder of Nebula Biocides

Together with his colleague Dr. Ansgar Schmidt-Bleker, also founder and CEO of Nebula Biocides GmbH, he had discovered the novel disinfection process in 2016. As part of their work at the Leibniz Institute for Plasma Science and Technology (INP), the physicists identified the substance peroxynitrite acid as active agent and developed the Sporosan® disinfectant on this basis. In this process, two starting components react with each other for a short time, providing a highly disinfecting effect during this period.

Sporosan® not only kills bacteria and viruses; even persistent bacterial spores have no chance of survival thanks to the new process.

Dr. Ansgar Schmidt-Bleker, founder of Nebula Biocides

In the future, this will also prevent infections with the dangerous hospital germ Clostridioides difficile, which leads to severe diarrhea and is often fatal, especially in previously ill patients. The researchers have thus achieved a breakthrough – so far there is no disinfectant with a comparably strong and rapid effect that is at the same time environmentally friendly and gentle in use.

The significance and potential of the active substance were also recognized by the three investors, whose participation enables the financing of studies required for regulatory compliance.

We are very proud to welcome Nebula Biocides with their highly disruptive chemical innovation to our portfolio. The underlying technology promises to create numerous sustainable application opportunities.

Dr. Nikolaus Raupp, Investment Manager at High-Tech Gründerfonds

With the help of the investors, the company, which now consists of a team of five, can pursue two paths at once: The approval of Sporosan® as a biocidal product, making it available for everyone as a hand and surface disinfectant by presumably 2028. In parallel, the Nebula team is working intensively on solutions for the sporicidal reprocessing of medical devices with the aim of marketing the disinfectant itself as a medical device. With the strategic investor, an industrial partner who is excited in using Sporosan® for his medical devices has already been found; market launch is expected in 2024. Furthermore, the start-up is already receiving inquiries from other interested companies from a wide range of industries every week, which underlines the broad significance of Nebula’s innovation in the healthcare, pharmaceutical and food sectors.

Team of Nebula Biocides: from left to right Dr. Ansgar Schmidt-Bleker, Anke Horsfield, Dr. Jörn Winter, Dr. Katja Fricke, Stefanie Schneider (Picture: Nebula Biocides)

About Nebula Biocides GmbH
Nebula Biocides GmbH was founded in 2019 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP) by the scientists Dr. Jörn Winter, Dr. Ansgar Schmidt-Bleker and the director of INP Prof. Dr. Klaus-Dieter Weltmann. With the aim of providing comprehensive protection against infectious pathogens, the company develops application-oriented disinfection solutions that reliably kill not only bacteria and viruses but also persistent bacterial spores.  

Press contact:
Nebula Biocides GmbH
Managing Directors: Dr. Jörn Winter, Dr. Ansgar Schmidt-Bleker
Brandteichstraße 20
17489 Greifswald
Phone: 03834-550701
E-Mail: info@nebula-biocides.de
Website: www.nebula-biocides.de

About Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern mbH
Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern mbH (MBMV) specializes in investments for small and medium-sized enterprises. It has been supporting regional SMEs in project financing for more than 28 years. So funding gaps can be closed and at the same time the equity base of small and medium-sized companies can be put on a broader footing. As a result of that promising ideas or future-oriented business strategies can be made possible more easily. Furthermore the MBMV is a reliable partner for startups and entrepreneurs as well.

www.mbm-v.de

Contact Investor
Mario Mietsch
mario.mietsch@bbm-v.de

About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 650 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3.5 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds. HTGF has also successfully sold interests in more than 140 companies.

Fund Investors in the public-private partnership include the Federal Ministry of Economics and Energy, KfW Capital, the Fraunhofer-Gesellschaft and 32 companies.

www.htgf.de/en

Media Contact
High-Tech Gründerfonds Management GmbH
Stefanie Grüter, Head of Marketing & Communications
T.: +49 228 82300 – 188
s.grueter@htgf.de

Investor Contact
High-Tech Gründerfonds Management GmbH
Dr. Nikolaus Raupp
T.: +49 228 82300 -185
n.raupp@htgf.de

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

More Press posts

Press
18. May 2022

Ventech, HTGF and Renown Business Angels Invest More than €4 Million in the Retail Tech Startup 7Learnings

7Learnings has secured more than €4 Million from Ventech (lead investor), HTGF and Celonis managers in its latest funding roundSince 2019, 7Learnings offers retailers a SaaS solution for machine learning-based pricing & marketing optimizationThe software increases profits for its clients by >10% on averageThe company targets to make its software the leading platform for retail optimization of tomorrow Berlin, May 18, 2022 - The start-up was founded in 2019 by Martin Nowak, Ei
 
Press
12. May 2022

Very successful exit for HTGF: AMCS to acquire Quentic – strong partners for a green future

With its modular SaaS solution, Quentic simplifies management and reporting in the fields of environmental, health, safety and quality (EHSQ) management and environment, social and governance (ESG).The acquisition by AMCS will further strengthen Quentic GmbH’s position as one of the leading providers of integrated software solutions in EHSQ and ESG.Together with a business angel, High-Tech Gründerfonds (HTGF) was the first investor in the company back in 2008 and has closely supported its
 
Press
3. May 2022

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

MUNICH, GERMANY, May 3, 2022 – Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), BioMedPartners, coparion, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners. The new capital will be used to advance Tubulis’ proprietary pipeline of